<DOC>
	<DOCNO>NCT01688011</DOCNO>
	<brief_summary>The purpose Connect® MDS/AML Disease Registry provide unique insight treatment regimens sequence regimen relate clinical outcome patient newly diagnose MDS , ICUS AML routine clinical practice evaluate molecular cellular marker may provide prognostic classification and/or might predictive therapy outcome .</brief_summary>
	<brief_title>Connect® MDS/AML Disease Registry</brief_title>
	<detailed_description>This Disease Registry collect data patient characteristic , treatment pattern clinical outcome . The objective describe newly diagnose MDS , ICUS AML patient treat ; build knowledge base regard effectiveness safety front-line subsequent treatment regimens community academic setting . Enrolled patient receive treatment evaluation MDS , ICUS AML accord standard care routine clinical practice study site . All treatment patient receive MDS , ICUS AML record , include initial treatment subsequent therapy . Data treatment outcome , include response rate measure treat physician , evidence progression , survival , patient-reported outcome collect quarterly electronic CRF .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients must able provide write informed consent Newly diagnose ( confirm diagnosis within 60 day prior date informed consent signature ) , primary secondary Myelodysplastic Syndromes ( MDS ) , Acute Myeloid Leukemia ( AML ) , Idiopathic Cytopenia Undetermined Significance ( ICUS ) Disease diagnosis confirm Central Eligibility Review AML patient must least 55 year age time inform consent signature MDS/ICUS patient must least 18 year age time inform consent signature Patients must willing able complete enrollment followup HRQoL instrument , patient must proficient either English Spanish Suspected proven acute promyelocytic leukemia ( APL ) ( FAB M3 WHO 2008 ) base morphology , immunophenotype , molecular assay karyotype MDS , AML ICUS cohort assignment Central Eligibility Review confirm site For MDS ICUS patient : receive active ( disease modify ) treatment** prior ICF date ( Supportive care transfusion , antibiotic , iron chelators , EPO , growth factor ( GCSF/GMCSF ) allow ) For AML patient : receive active ( disease modify ) treatment** initiate 2 week ( 14 day ) prior ICF date ( Supportive care , , transfusion , antibiotic , iron chelators , EPO , growth factor ( GCSF/GMCSF ) , tumor lysis prophylaxis allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myelodysplastic Syndromes</keyword>
	<keyword>MDS</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Registry</keyword>
	<keyword>Connect®</keyword>
</DOC>